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In recent years, mild hyperthermia (40-45°C) has been increasingly investigated as an 
adjuvant that can effectively sensitize tumors to chemotherapy and radiotherapy as well as 
induce apoptosis.[1] In particular, magnetic hyperthermia, wherein the exposure of magnetic 
nanoparticles (MNPs) to an alternating magnetic field (AMF) results in the induction of 
hyperthermia via Neel and Brownian relaxation, represents an attractive approach for the 
selective heating of tumors while sparing surrounding healthy tissues.[2] However, the 
treatment of tumors with magnetic hyperthermia results in a number of molecular effects 
including a sharp increase in the synthesis of heat shock proteins (HSPs), whose 
fundamental function is to protect cellular proteins from degradation. It has been reported 
that these effects occur through numerous signaling pathways involved in therapeutic 
resistance including the activation of DNA repair mechanisms (via the BRCA family)[3] and 
the inhibition of apoptosis (via the Akt/PI3K pathway).[4, 5] As such, HSP expression 
following magnetic hyperthermia significantly hinders MNP-mediated apoptosis in cancer 
cells. For instance, it has been demonstrated that the activation of HSPs preserves cancer 
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A number of therapeutics are currently being investigated for their ability to target HSP-
related pathways. For example, the proteasome inhibitor, bortezimab, targets the NF-kB 
pathway, which is in part regulated by HSP70 and HSP90.[7] There are also agents directed 
at the HSP90 and mTOR/HIF pathways including the inhibitor geldanamycin.[8] For 
instance, Yoo et al. developed resistance-free apoptosis-inducing magnetic nanoparticles 
(RAIN) composed of MNPs that release geldanamycin to inhibit HSP90 and induce 
magnetic hyperthermia upon exposure to an AMF.[9] While promising, each individual of 
the HSP family (e.g. HSP27, HSP70, HSP72, HSP90) has numerous subsequent targets 
whose pathways have significant degeneracy.[10] Therefore, to maximize the therapeutic 
potential of magnetic hyperthermia for the treatment of cancer, there is a clear need to 
simultaneously target the multiple key downstream effectors of HSPs that promote cell 
survival and inhibit apoptosis following treatment.
Herein, we report the novel application of highly magnetic zinc-doped iron oxide 
nanoparticles (ZnFe2O4) for the dual purpose of delivering a microRNA (miRNA) that 
targets multiple downstream pathways modulated by HSPs and inducing magnetic 
hyperthermia to enhance the treatment of cancer cells (Figure 1a). Specifically, in this 
study, glioblastoma multiforme (GBM) brain cancer cells were used as a model system. 
miRNAs are small endogenous noncoding RNA molecules that interact with target 
messenger RNAs (mRNAs) to down-regulate or inhibit translation. The function of miRNAs 
in cancer formation and treatment is well established.[11] However, the unique feature that 
makes miRNA particularly suitable to combine with magnetic hyperthermia is their ability 
to have multiple, possibly hundreds of, targets.[12] Moreover, these targets are often on the 
same or similar pathways. Therefore, the delivery of a single miRNA can potentially have a 
greater, more cumulative effect on HSPs and their downstream effectors than delivering 
other types of therapeutic molecules such as small interfering RNA (siRNA) molecules or 
drugs, which can only modulate single HSP-related targets.[13] To this end, we are interested 
in delivering lethal-7a miRNA (let-7a), which is known to be a tumor suppressor that 
inhibits malignant growth by targeting factors such as the BRCA family, RAS, IGF1R, and 
c-Myc, which overlap with a number of key downstream effectors of HSPs.[14] Moreover, 
let-7a has been reported to be down-regulated in a number of cancer types including cancers 
of the prostate, breast, and brain, where let-7a is decreased by over 3-fold compared to 
healthy surrounding tissue.[15] As such, we hypothesized that the MNP-mediated delivery of 
let-7a should act synergistically with magnetic hyperthermia to enhance hyperthermia-
mediated apoptosis by targeting multiple key HSP-related pathways including DNA repair 
and cell survival (via IGF1R and RAS) mechanisms.
For the MNP-based combined miRNA and magnetic hyperthermia therapy, we utilized zinc 
doped iron oxide (ZnFe2O4) nanoparticles. These MNPs have previously been shown to 
have a significantly higher magnetic susceptibility and hence, can afford improved magnetic 
properties while requiring a much lower dose when compared to conventional Fe2O3 or 
Fe3O4 nanoparticles.[16] As such, we first synthesized ZnFe2O4 MNPs with a doping 
percentage of (Zn0.4Fe0.6)Fe2O4 via the thermal decomposition of a mixture of metal 
precursors (zinc chloride, ferrous chloride, and ferric acetylacetonate) in the presence of 
oleic acid using a previously reported protocol that was modified by our group.[16, 17] The 
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resulting highly monodisperse and hydrophobic ZnFe2O4 MNPs were then made water-
soluble via ligand exchange with 2, 3-dimercaptosuccinic acid (DMSA).[18] Transmission 
electron microscopy (TEM) analysis revealed that the overall diameter of the ZnFe2O4 
MNPs was 22.92 ± 3.7 nm (Figure 1c). A high-resolution TEM image shows the 
monocrystalline structure of the MNPs with a lattice fringe that was measured to be 0.296 
nm (Inset of Figure 1c), which is characteristic of the (220) planes of the spinel and is in 
agreement with previous reports.[16, 17] In terms of the water soluble MNPs, it was found 
that the DMSA coated MNPs had a hydrodynamic size of 30.1 ± 2.8 nm (polydispersity 
index [PDI] = 0.192) as measured by dynamic light scattering (DLS) and a zeta potential of 
-23.3 ± 1.3 mV. Moreover, with regard to their magnetic properties, the MNPs were 
characterized by a specific absorption rate (SAR) of 341 W/g, which was determined using 
an AMF with an amplitude of 5 kA/m and a frequency of 225 kHz. This SAR is consistent 
with data reported in the literature for similar ZnFe2O4 MNPs.[19] In comparison, we found 
that conventional Fe3O4 MNPs (7 nm diameter) have a SAR of 28.46 W/g, which is also in 
agreement with values that have been reported (10-40 W/g).[20] As such, our monodisperse 
water soluble ZnFe2O4MNPs are characterized by expectedly superior magnetic properties 
thereby allowing for the use of significantly lower doses when compared to conventional 
MNPs.
To prepare the aforementioned ZnFe2O4 MNPs for miRNA delivery, the negatively charged 
water-soluble MNPs were coated with a 10 kDa branched cationic polymer, 
polyethyleneimine (PEI), which affords the MNPs with an overall positive charge. PEI is a 
polymer that is partially protonated under physiological conditions, thus allowing for the 
formation of complexes in the presence of nucleic acids. Previous studies have shown that a 
direct relationship exists between the molecular weight of PEI and cytotoxicity.[21] 
Therefore, to minimize cytotoxicity while maximizing transfection efficiency we used 10 
kDa branched PEI (Figure S1a). In particular, to deliver miRNAs efficiently using our 
MNPs, we developed a two-step layer-by-layer process (Figure 1b). First, the PEI-coated 
MNPs (1 μg/mL) were incubated with miRNA in an 80 mM NaCl solution. Afterwards, an 
outer coat of PEI was added to provide additional protection for the miRNA as well as to 
facilitate cell uptake and endosomal escape. We observed that the size of the MNP 
complexes increased to a final diameter of 76.91 ± 11 nm (PDI = 0.242) for the layer-by-
layer MNP-PEI/miRNA/PEI complex and had a positive zeta potential of +23.7 ± 1.7 mV. 
Moreover, a reversal of the zeta potential was observed after the deposition of each layer 
(Figure S1b). A more detailed description of the optimization process for MNP complex 
formation can be found in the supporting information (Figure S1).
To assess the efficiency of cellular uptake, we performed fluorescence microscopy on GBM 
cells (U87-EGFRvIII) that were transfected with MNP-PEI/miRNA/PEI complexes (Figure 
1d). In this case, the MNP complexes were assembled using 100 nM Cy3-labeled scrambled 
precursor miRNA (Ambion) and delivery was enhanced by magnetofection, a well-
established method that allows for the rapid accumulation of MNPs and their payloads upon 
exposure to an external magnetic field.[17, 22] Twenty-four hours after transfection, we 
visualized and quantified the efficiency of uptake. We found that that the GBM cells were 
able to efficiently uptake the MNP-PEI/Cy3-miRNA/PEI complexes (98% efficiency). 
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Moreover, compared to commercially available transfection agents (X-tremeGENE®), the 
fluorescence intensity of Cy3-miRNA uptaken after magnetofection using our layer-by-layer 
MNP complexes was significantly greater (Figure S2). To further confirm MNP uptake, 
cross-sectional cellular images were obtained using TEM (Figure S3). Finally, in contrast to 
other cationic transfection methods, which can result in low cell viabilities,[23] the MNP 
complexes and the process of magnetofection caused little to no cell death (92% cell 
viability) owing to the much lower concentration and shorter time of incubation that is 
necessary. As such, this demonstrates that these complexes can be used for extended 
incubation and downstream applications such as magnetic hyperthermia or imaging (Figure 
S4a).
As mentioned previously, let-7a is known to target a number of genes involved in cell 
survival (PI3K via IGF1R)[4, 5] and proliferation (RAS)[24] (Figure 2a). To confirm this in 
GBM, we first delivered 70-nucleotide precursor let-7a miRNA (100 nM) to U87-EGFRvIII 
GBM cells using our optimized MNP-based delivery conditions and quantified the mRNA 
expression levels of selected let-7a targets. Specifically, using quantitative PCR (qPCR) 
measurements made from total RNA, we observed at least 40% down-regulation (p < 0.05) 
of all target gene transcripts (KRAS, NRAS, c-MYC, and IGF1R) relative to U87-EGFRvIII 
cells treated with scrambled miRNA (100 nM) as delivered by our MNPs (Figure 2b; 
Figure S5). This is also supported by Lee et al., who reported that let-7 can inhibit 
proliferation in GBM cells (e.g. U251 and U87) via the down regulation of NRAS and 
KRAS.[25] These results not only confirm that let-7a targets the desired genes in GBM cells 
but also that the function and target-specificity of let-7a is retained upon cellular uptake/
endosomal escape.
Next, to induce apoptosis and evaluate the therapeutic potential of let-7a, we modulated 
intracellular levels of this miRNA. We observed that 48 hours after the MNP-mediated 
delivery of let-7a, GBM cell viability decreased significantly compared to scrambled 
miRNA controls in a dose-dependent fashion (Figure 2c). Using 100 nM miRNA as the 
optimal concentration for the remainder of the studies, apoptosis levels in the GBM cells 
were evaluated using Annexin-V/propidium iodide staining and qPCR of caspase-3 
expression. In particular, FACS analysis of Annexin-V/propidium iodide stained cells 
demonstrated that significantly more cells underwent apoptosis after treatment with let-7a 
(Figure 2d) compared to scrambled miRNA controls. Similarly, the expression of caspase-3 
was up regulated by 30% (p < 0.05) after treatment with let-7a as compared to scrambled 
miRNA control (Figure 2e).
In terms of the effect that let-7a delivery has on key signaling pathways, we observed that 
the delivery of let-7a to GBM cells resulted in a significant decrease in the expression of 
PI3K (56% decrease, p < 0.05), which typically promotes cell survival and inhibits 
apoptosis.[26] As PI3K is downstream of let-7a targets including RAS and IGF1R (Figure 
2a),[27] this result suggests that let-7a induces apoptosis in GBM cells via the targeting of 
RAS and IGF1R. Finally, we investigated the efficacy of let-7a delivery to other GBM cell 
lines (U87-WT, U87-EGFR) as well as normal brain cells (astrocytes) (Figure S4b). We 
found that let-7a appears to be most effective in U87-EGFRvIII cells compared to U87-WT 
and U87-EGFR cells possibly because the U87-EGFRvIII cell line overexpresses EGFRvIII, 
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which is upstream of PI3K.[24] Moreover, we observed that let-7a does not induce 
cytotoxicity in normal brain cells (astrocytes), which is expected as non-cancer cells should 
have much higher endogenous levels of let-7a compared to brain cancer cells.[15]
To evaluate the ability of our MNP complexes to induce magnetic hyperthermia, we 
delivered MNP-PEI (10 μg/mL, Figure S6a) to U87-EGFRvIII cells. Twenty-four hours 
after treatment, the MNP-PEI transfected cells were trypsinized and exposed to an AMF (5 
kA/m, 225 kHz). We found that the therapeutic effect of magnetic hyperthermia was dose-
dependent with the lowest cell viability (63.14%) being achieved after 45 minutes of 
exposure to an AMF (Figure 3a). Moreover, an increase in the level of apoptosis was 
observed as quantified via Annexin-V/PI staining (Figure 3b) and the mRNA expression 
level of caspase-3 (2 fold increase) when compared to control cells transfected with MNPs 
but not exposed to an AMF (Figure 3c). Finally, to determine the approximate temperature 
that was achieved at this MNP concentration, we monitored the temperature of the solution 
containing GBM cells that had been transfected with 10 μg/mL of MNPs using a fiber optic 
temperature probe. We observed that after 45 minutes of exposure to an AMF, an 
approximate temperature of 44.1°C was reached (Figure 3d).
To study the effect that hyperthermia has on the expression of HSPs and the activation of 
their downstream effectors, we confirmed that magnetic hyperthermia significantly increases 
the expression of HSPs including HSP70 (4.1 fold, p < 0.005), HSP72 (5.4 fold, p < 0.001), 
and HSP90 (2.9 fold, p < 0.05), which have all been implicated in cancer progression and 
chemoresistance (Figure 3c).[28, 29] Moreover, downstream effectors of these HSPs such as 
IGF1R, RAS, and PI3K, which are well-known to inhibit apoptosis and promote cell 
survival, are also significantly activated (p < 0.01) when compared to controls that have not 
been exposed to magnetic hyperthermia (Figure 3e; Figure S7). As such, while MNP-
mediated magnetic hyperthermia does induce significant toxicity in GBM cells, the 
activation of pathways that promote cell survival and inhibit apoptosis is also apparent 
suggesting that the inhibition of these multiple key downstream effectors can potentially 
improve the therapeutic effects of MNP-mediated magnetic hyperthermia.
To test the hypothesis that the MNP-based combined miRNA and magnetic hyperthermia 
therapy would enhance the therapeutic effects of let-7a delivery or magnetic hyperthermia 
alone, we delivered MNP-PEI/miRNA/PEI complexes to U87-EGFRvIII cells. Twenty-four 
hours after treatment, the cells were trypsinized and exposed to an AMF. This treatment 
sequence, as depicted in Figure 4a, was chosen because an independent study demonstrated 
it to be the optimal treatment time for combined therapy (Figure S6b). This is expected as 
the maximal effects of magnetic hyperthermia are typically seen within 24 hours whereas 
miRNAs such as let-7a act over 48-72 hours. Overall, combined MNP-based let-7a delivery 
and magnetic hyperthermia exhibited an additive effect resulting in a cell viability as low as 
34% (Figure 4b), which is significantly lower than either let-7a treatment (69.8%, p < 0.01) 
or magnetic hyperthermia alone (63.14%, p < 0.05). Moreover, a significant increase in 
apoptosis levels was observed as quantified via Annexin-V/PI staining (Figure 4c) and the 
mRNA expression of caspase-3 (80% increase) when compared to either let-7a treatment or 
magnetic hyperthermia alone (Figure 4d). To further demonstrate the potential of our 
combined MNP-based let-7a delivery and magnetic hyperthermia therapy, we utilized a 
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tumor spheroid monoculture assay as an intermediate between in vitro monolayer-based 
models and future in vivo studies. Specifically, unlike classical monolayer-based models, 
tumor spheroid models are able to mirror the three-dimensional (3D) context of in vivo 
tumors to a high degree and can provide more therapeutically relevant results.[30] In 
particular, we observed that upon exposure to combined therapy using the same conditions 
as those used in monolayer cell cultures, we saw a similar additive effect resulting in tumor 
spheroid cell viability as low as 47% (Figure S9). As expected of a 3D environment, 
although still effective, combined therapy was not as effective as in monolayer cultures 
across all conditions (e.g. let-7a alone, magnetic hyperthermia alone, and combined 
therapy). Finally, as a preliminary in vivo study, we performed a biodistribution study 
wherein MNP complexes (25 and 50 mg MNP/kg of body weight) functionalized with 
poly(ethylene glycol) (PEG; molecular weight = 2,000) and targeted via anti-CD44 
antibodies were injected (tail-vein injection) into nu/nu mice implanted with subcutaneous 
SUM159 xenografts. We found that the animals tolerated both doses well and that the MNPs 
were able to localize/target the tumors within one week of injection (Figures S10). While 
more detailed in vivo studies remain to be performed, our findings taken together with 
previous evidence demonstrating the effectiveness of let-7 alone in vivo[25] and magnetic 
hyperthermia alone in vivo[2, 31] suggests that combined MNP-based let-7a delivery and 
magnetic hyperthermia will be able to act as an effective treatment in vivo.
Finally, to examine the molecular mechanisms by which MNP-based combined let-7 and 
magnetic hyperthermia therapy can increase cell death in GBM cells, we investigated its 
target genes focusing on those related to HSPs as well as cell survival and proliferation 
(Figure 4d; Figure S8). Specifically, we observed that PI3K expression was significantly 
down regulated (23% decrease, p < 0.001) whereas caspase-3 was significantly up regulated 
(80% increase, p < 0.001) when magnetic hyperthermia was combined with let-7a delivery 
(Figure 4d). Moreover, the expression of HSPs was also significantly down regulated 
(>20%, p < 0.02) when compared to magnetic hyperthermia treated control cells. In terms of 
let-7a targets, the expression of RAS, IGF1R, and MYC were down regulated significantly 
after exposure to combined therapy (Figure 4e; Figures S8). These results suggest that the 
down regulation of pathways including IGF1R and RAS, which directly activate PI3K,[27] 
by let-7a may lead to a greater increase in caspase-3 mediated apoptosis than would 
otherwise be possible with magnetic hyperthermia or let-7a delivery alone. Moreover, it has 
been shown that the inhibition of PI3K can also down regulate HSPs,[31] which is supported 
by the down regulation of HSP that is observed in our results (Figure 4d), further pushing 
GBM cells towards apoptosis following combined therapy. Together, these results suggest 
that the MNP-based combination of let-7a delivery followed by magnetic hyperthermia may 
significantly enhance the treatment of GBM.
In summary, we have successfully demonstrated the effective MNP-based delivery of 
miRNA to cancer cells as well as the novel combined MNP-based miRNA and magnetic 
hyperthermia therapy to enhance apoptosis in cancer cells. As mentioned previously, to 
maximize the therapeutic effects of hyperthermia, a number of therapeutics have been 
developed to target HSP-mediated pathways including the HSP70 and HSP90 inhibitor, 
bortezimab[7] and geldanamycin, which targets HSP90.[8] While promising, each individual 
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of the HSP family (e.g. HSP27, HSP70, HSP72, HSP90) has numerous subsequent 
targets.[10] As such, in this study we sought to deliver a miRNA (let-7a), which 
simultaneously targets multiple key downstream effectors of HSPs on a MNP platform that 
also acts as an excellent magnetic hyperthermia agent to enhance apoptosis in brain cancer 
cells. The results indicate that combined MNP-based let-7a delivery and magnetic 
hyperthermia showed an additive effect resulting in significantly more apoptosis in brain 
cancer cells than either let-7a treatment or magnetic hyperthermia alone. Moreover, our 
results suggest that the targeting of pathways such as IGF1R and RAS by let-7a may lead to 
an increase in caspase-3 mediated apoptosis. Finally, besides enhancing the effects of 
magnetic hyperthermia, combined MNP-based let-7a delivery and magnetic hyperthermia 
can also offer a number of other advantages. First, the use of MNPs allows for enhancement 
of transfection using magnetofection as well as magnetic targeting. Second, treatment can 
potentially be monitored via magnetic resonance imaging (MRI) owing to the use of MNPs. 
Finally, we believe this treatment strategy can enhance the therapeutic potential of magnetic 
hyperthermia and by choosing cancer-specific miRNAs, can even be applied to enhance the 
treatment of other cancers and cancer stem cells including, but not limited to, breast and 
prostate cancers. In the future, we plan to improve targeting and biocompabilitity by the 
addition of targeting ligands (e.g. iRGD) and polyethylene glycol (PEG), respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We would like to thank Dr. Jae-Younh So and Prof. Nanjoo Suh for their help with the animal studies and in vivo 
imaging. We would also like to thank Mr. Valentine Starovoytov for his help with TEM imaging. The work was 
supported by the NIH Director's Innovator Award [(1DP20D006462-01), K.B.L]. P.T.Y. would also like to 
acknowledge the NIH Biotechnology Training Grant for support.
REFERENCES
1. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. The 
lancet oncology. 2002; 3(8):487–97. [PubMed: 12147435] 
2. Kumar CS, Mohammad F. Adv Drug Deliv Rev. 2011; 63(9):789–808. DOI 10.1016/j.addr.
2011.03.008. [PubMed: 21447363] 
3. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Gynecologic oncology. 2010; 117(2):177–82. 
DOI 10.1016/j.ygyno.2009.10.078. [PubMed: 19942270] 
4. Garrido C, Solary E. Cell Death Differ. 2003; 10(6):619–620. DOI 10.1038/Sj.Cdd.4401229. 
[PubMed: 12761570] 
5. Takayama S, Reed JC, Homma S. Oncogene. 2003; 22(56):9041–9047. DOI 10.1038/Sj.Onc.
1207114. [PubMed: 14663482] 
6. Jolly C, Morimoto RI. J Natl Cancer I. 2000; 92(19):1564–1572. DOI 10.1093/jnci/92.19.1564. 
7. Minnnaugh EG, Xu WP, Vos M, Yuan XT, Isaacs JS, Bisht KS, Gius D, Neckers L. Mol Cancer 
Ther. 2004; 3(5):551–566. [PubMed: 15141013] 
8. Miyata Y. Curr Pharm Design. 2005; 11(9):1131–1138. DOI 10.2174/1381612053507585. 
9. Yoo D, Jeong H, Noh SH, Lee JH, Cheon J. Angewandte Chemie. 2013; 52(49):13047–51. DOI 
10.1002/anie.201306557. [PubMed: 24281889] 
10. Ciocca DR, Calderwood SK. Cell stress & chaperones. 2005; 10(2):86–103. [PubMed: 16038406] 
Yin et al. Page 7













11. Calin GA, Croce CM. Nature reviews. Cancer. 2006; 6(11):857–66. DOI 10.1038/nrc1997. 
[PubMed: 17060945] 
12. Bartel DP. Cell. 2009; 136(2):215–233. DOI 10.1016/J.Cell.2009.01.002. [PubMed: 19167326] 
13. Bader AG, Brown D, Winkler M. Cancer research. 2010; 70(18):7027–30. DOI 
10.1158/0008-5472.CAN-10-2010. [PubMed: 20807816] 
14. Roush S, Slack FJ. Trends in cell biology. 2008; 18(10):505–16. DOI 10.1016/j.tcb.2008.07.007. 
[PubMed: 18774294] 
15. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Cohen MA, Zelikovitch B, 
Shoshan Y, Spektor S, Reubinoff BE, Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T. Neuro-
Oncology. 2010; 12(5):422–433. DOI 10.1093/Neuonc/Nop061. [PubMed: 20406893] 
16. Jang JT, Nah H, Lee JH, Moon SH, Kim MG, Cheon J. Angew Chem Int Ed Engl. 2009; 48(7):
1234–8. DOI 10.1002/anie.200805149. [PubMed: 19137514] 
17. Shah B, Yin PT, Ghoshal S, Lee KB. Angew Chem Int Edit. 2013; 52(24):6190–6195. DOI 
10.1002/anie.201302245. 
18. Guo ST, Huang YY, Jiang QA, Sun Y, Deng LD, Liang ZC, Du QA, Xing JF, Zhao YL, Wang PC, 
Dong AJ, Liang XJ. Acs Nano. 2010; 4(9):5505–5511. DOI 10.1021/Nn101638u. [PubMed: 
20707386] 
19. Zelis PM, Pasquevich GA, Stewart SJ, van Raap MBF, Aphesteguy J, Bruvera IJ, Laborde C, 
Pianciola B, Jacobo S, Sanchez FH. J Phys D Appl Phys. 2013; 46(12) DOI 
10.1088/0022-3727/46/12/125006. 
20. Drake P, Cho HJ, Shih PS, Kao CH, Lee KF, Kuo CH, Lin XZ, Lin YJ. J Mater Chem. 2007; 
17(46):4914–4918. DOI 10.1039/B711962c. 
21. Werth S, Urban-Klein B, Dai L, Hobel S, Grzelinski M, Bakowsky U, Czubayko F, Aigner A. 
Journal of controlled release : official journal of the Controlled Release Society. 2006; 112(2):
257–70. DOI 10.1016/j.jconrel.2006.02.009. [PubMed: 16574264] 
22. Plank C, Zelphati O, Mykhaylyk O. Adv Drug Deliv Rev. 2011; 63(14-15):1300–31. DOI 10.1016/
j.addr.2011.08.002. [PubMed: 21893135] 
23. Lv H, Zhang S, Wang B, Cui S, Yan J. Journal of controlled release : official journal of the 
Controlled Release Society. 2006; 114(1):100–9. DOI 10.1016/j.jconrel.2006.04.014. [PubMed: 
16831482] 
24. Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, 
Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI, Altshuler D, Daley GQ, 
Consortium D, Investigators M. Cell. 2011; 147(1):81–94. DOI 10.1016/J.Cell.2011.08.033. 
[PubMed: 21962509] 
25. Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, Park CK, Jung KH, Lee SK, Kim M, Roh JK. 
Journal of neuro-oncology. 2011; 102(1):19–24. DOI 10.1007/s11060-010-0286-6. [PubMed: 
20607356] 
26. Datta SR, Brunet A, Greenberg ME. Gene Dev. 1999; 13(22):2905–2927. DOI 10.1101/gad.
13.22.2905. [PubMed: 10579998] 
27. Bielen A, Perryman L, Box GM, Valenti M, Brandon AD, Martins V, Jury A, Popov S, Gowan S, 
Jeay S, Raynaud FI, Hofmann F, Hargrave D, Eccles SA, Jones C. Mol Cancer Ther. 2011; 10(8):
1407–1418. DOI 10.1158/1535-7163.Mct-11-0205. [PubMed: 21659463] 
28. Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M. Neurology. 2000; 54(6):
1357–1365. [PubMed: 10746610] 
29. Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T. 
Cancer Immunol Immun. 2003; 52(2):80–88. DOI 10.1007/S00262-002-0335-X. 
30. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. J 
Biotechnol. 2010; 148(1):3–15. DOI 10.1016/j.jbiotec.2010.01.012. [PubMed: 20097238] 
31. Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, Sibov TT, Amaro E 
Jr. Tannús A, Vidoto EL, Martins MJ, Santos RS, Gamarra LF. Int J Nanomedicine. 2011; 6:591–
603. DOI 10.2147/IJN.S14737. [PubMed: 21674016] 
32. Zhou J, Schmid T, Frank R, Brune B. J Biol Chem. 2004; 279(14):13506–13513. DOI 10.1074/
Jbc.M310164200. [PubMed: 14726529] 
Yin et al. Page 8














Magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance the treatment 
brain cancer. (a) MNP complexes are first delivered to GBM cells, which is enhanced by 
magnetofection. Once inside the cell, let-7a miRNA is released thereby targeting 
downstream effectors of HSPs. This sensitizes the cancer cells to subsequent magnetic 
hyperthermia enhancing apoptosis. (b) MNPs will be complexed with let-7a miRNA using 
10 kDa branched PEI via a layer-by-layer approach. (c) TEM micrograph of the MNPs 
(scale bar = 20 nm). Inset: High resolution TEM micrograph of the MNPs showing the 
lattice fringes (scale bar = 10 nm). (d) U87-EGFRvIII GBM cells readily uptake MNPs 
complexed with Cy3-labeled scrambled miRNA following magnetofection (scale bar = 50 
μm). Blue = hoescht stained nuclei, red = cy3-labeled scrambled miRNA.
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Magnetic nanoparticle-based let-7a delivery. (a) The delivery of let-7a can inhibit targets 
such as IGF1R, RAS, HMGA2, and c-MYC, which typically promote proliferation and cell 
survival while inhibiting apoptosis. (b) The delivery of let-7a to U87-EGFRvIII GBM cells 
significantly down-regulates expected targets of let-7a compared to scrambled miRNA 
controls as determined by qPCR (*p < 0.05, **p < 0.01). (c) Cell viability as quantified by 
MTS assay 48 hours after initial transfection with let-7a. Samples were normalized to 
untreated controls. (d) FACS analysis of Annexin-V and propidium iodide stained cells. (e) 
qPCR of downstream targets of let-7a compared to scrambled miRNA controls (*p < 0.05).
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Magnetic nanoparticle-based magnetic hyperthermia. (a) MTS assay following the induction 
of magnetic hyperthermia (10 μg/mL MNP) in U87-EGFRvIII GBM cells. Conditions were 
assayed 48 hours after transfection and normalized to MNP controls (without exposure to 
AMF). (b) FACS analysis of Annexin-V and propidium iodide stained cells with and 
without treatment. (c) qPCR illustrates that, following magnetic hyperthermia, caspase-3 is 
significantly up regulated as are HSPs. Results were normalized to MNP controls without 
magnetic hyperthermia (*p < 0.05, **p < 0.01, N.S. = no significance). (d) The temperature 
of the solution was monitored using a fiber optic temperature probe (Lumasense) over the 
course of magnetic hyperthermia. Control consisted of the same conditions but without 
MNPs. (e) qPCR shows up regulation of let-7a targets following magnetic hyperthermia. 
Again, results were normalized to MNP controls in the absence of magnetic hyperthermia 
(*p < 0.01, **p < 0.001).
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Combined magnetic nanoparticle-based let-7a delivery and magnetic hyperthermia therapy. 
(a) Timeline of combined treatment. (b) Cell viability following combined let-7a delivery 
and magnetic hyperthermia as quantified by MTS assay (*p < 0.05, **p < 0.01). (c) FACS 
analysis of combination treated cells compared to controls. (d) Combined let-7a delivery and 
magnetic hyperthermia results in up regulation of caspase-3 and a decrease in PI3K as well 
as HSPs as determined by qPCR (*p < 0.05, **p < 0.01). (e) qPCR analysis of let-7a targets 
following combined therapy (*p < 0.05, **p < 0.01). qPCR results were normalized to 
MNP-PEI/miRNA/PEI complex controls delivering scrambled miRNA without exposure to 
magnetic hyperthermia.
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